Literature DB >> 15168789

The effect of different lipid components on the in vitro stability and release kinetics of liposome formulations.

Michael Anderson1, Abdelwahab Omri.   

Abstract

Liposomes are colloidal carriers that form when certain (phospho)lipid molecules are hydrated in an aqueous media with some energy input. The ideal liposome formulation with optimum stability will improve drug delivery by decreasing the required dose and increasing the efficacy of the entrapped drug at the target organ or tissue. The most important parameter of interest in this article was to compare the efficacy of three different liposomes formulated with DSPC, DMPC, and DPPC, all saturated neutral phospholipids with different acyl chain lengths and transition temperatures. DMPC has a phase transition temperature (Tc) below 37 degrees C, whereas the other two phospholipids possess Tcs above the physiological temperature. These lipids were then added to a cholesterol concentration of 21% to optimize the stability of the vesicles. The liposomes were prepared by a sonication and incubated in phosphate buffered saline (PBS) at 4 degrees C and 37 degrees C. The encapsulation efficiency, initial size, and drug retention of the vesicles were tested over a 48-hr period employing radiolabeled inulin as a model drug. The phase transition temperature of liposomes, which depends on the Tc of the constituent lipids, was an important factor in liposome stability. Of all the liposomes tested, the greatest encapsulation efficiency was found for the DSPC liposomes (2.95%) that also had the greatest drug retention over 48 hr at both 4 degrees C (87.1 +/- 6.8%) and 37 degrees C (85.2 +/- 10.1%), none of these values being significantly different from time zero. The lowest drug retention was found for DMPC liposomes for which a significant difference in drug retention was seen after only 15 min at both 4 degrees C (47.3 +/- 6.9%) and 37 degrees C (53.8 +/- 4.3%). The DPPC liposomes showed a significant difference in drug retention after 3 hr at 4 degrees C (62.1 +/- 8.2%) and after 24 hr at 37 degrees C (60.8 +/- 8.9%). Following the initial drop at certain time intervals a plateau was reached for all of the liposome formulations after which no significant difference in drug retention was observed. In conclusion, liposomes with higher transition temperatures appear to be more stable in PBS either at 4 degrees C or 37 degrees C, indicating that the increase in acyl chain length (and therefore transition temperature) is directly proportional to stability.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15168789     DOI: 10.1080/10717540490265243

Source DB:  PubMed          Journal:  Drug Deliv        ISSN: 1071-7544            Impact factor:   6.419


  38 in total

1.  Pharmacokinetic stability of macrocyclic peptide triazole HIV-1 inactivators alone and in liposomes.

Authors:  Rachna Aneja; Antonella Grigoletto; Aakansha Nangarlia; Adel A Rashad; Steven Wrenn; Jeffrey M Jacobson; Gianfranco Pasut; Irwin Chaiken
Journal:  J Pept Sci       Date:  2019-02-27       Impact factor: 1.905

2.  Optimization of RGD-modified Nano-liposomes Encapsulating Eptifibatide.

Authors:  Hassan Bardania; Seyed Abbas Shojaosadati; Farzad Kobarfard; Farid Dorkoosh
Journal:  Iran J Biotechnol       Date:  2016-06       Impact factor: 1.671

3.  Iloprost-containing liposomes for aerosol application in pulmonary arterial hypertension: formulation aspects and stability.

Authors:  Elke Kleemann; Thomas Schmehl; Tobias Gessler; Udo Bakowsky; Thomas Kissel; Werner Seeger
Journal:  Pharm Res       Date:  2006-12-27       Impact factor: 4.200

Review 4.  Role of In Vitro Release Methods in Liposomal Formulation Development: Challenges and Regulatory Perspective.

Authors:  Deepak Solomon; Nilesh Gupta; Nihal S Mulla; Snehal Shukla; Yadir A Guerrero; Vivek Gupta
Journal:  AAPS J       Date:  2017-09-18       Impact factor: 4.009

5.  Radio Frequency-Activated Nanoliposomes for Controlled Combination Drug Delivery.

Authors:  Swapnil A Malekar; Ashish L Sarode; Alvin C Bach; Arijit Bose; Geoffrey Bothun; David R Worthen
Journal:  AAPS PharmSciTech       Date:  2015-04-22       Impact factor: 3.246

6.  Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors.

Authors:  Mai Alhajlan; Moayad Alhariri; Abdelwahab Omri
Journal:  Antimicrob Agents Chemother       Date:  2013-04-01       Impact factor: 5.191

7.  Encapsulation of eptifibatide in RGD-modified nanoliposomes improves platelet aggregation inhibitory activity.

Authors:  Hassan Bardania; Seyed Abbas Shojaosadati; Farzad Kobarfard; Farid Dorkoosh; Marjan Esfahani Zadeh; Mahmoud Naraki; Mehrdad Faizi
Journal:  J Thromb Thrombolysis       Date:  2017-02       Impact factor: 2.300

8.  A Study of Liposomal Formulations to Improve the Delivery of Aquated Cisplatin to a Multidrug Resistant Tumor.

Authors:  Yucheng Zhao; Jonathan P May; I-Wen Chen; Elijus Undzys; Shyh-Dar Li
Journal:  Pharm Res       Date:  2015-05-12       Impact factor: 4.200

Review 9.  Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.

Authors:  Phatsapong Yingchoncharoen; Danuta S Kalinowski; Des R Richardson
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

10.  Physicochemical properties of epidermal growth factor receptor inhibitors and development of a nanoliposomal formulation of gefitinib.

Authors:  Brian J Trummer; Vandana Iyer; Sathy V Balu-Iyer; Robert O'Connor; Robert M Straubinger
Journal:  J Pharm Sci       Date:  2012-05-11       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.